Advanced cell therapy for the treatment of osteochondral defects: from product devel-opment to the clinical trial

      Osteochondral injuries are common in humans and are relatively difficult to manage with current treatment options. The use of autologous expanded progenitor or stem cells provides a source of therapeutic and immunologically compatible medicines that can be used in regenerative medicine. We herein present the development of an advanced therapy medicinal product (namely mesenchymal stromal cells, MSC) from the preclinical stage to the completion of Phase I/IIa clinical trial (EUDRA-CT: 2009-016449-24; Identifier: NCT01227694).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect